Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New COPD Candidates Could Get Hung Up On Safety Concerns

Executive Summary

FDA is facing several novel candidates for chronic obstructive pulmonary disease in 2013; those products should expect close scrutiny due to past issues with class safety and new signals in clinical trials.

You may also be interested in...

Aquinox Pulls In $18M In Venture Funds As COPD Drug Moves Forward

The Canadian company will use the funds from its Series C financing to advance its lead drug candidate through Phase II testing in two indications, including COPD.

GSK’s Breo Ellipta Gets “Snowquestered” As FDA Delays Advisory Cmte

FDA missed its deadline to post the advisory committee briefing materials then postponed the meeting as a winter storm headed towards Washington.

Business News, In Brief

Quintiles files IPO; Forest sees LAMA/LABA combo product, slated for a 2014 NDA, as filling out a suite of COPD drugs to cover the full range of disease severity. Plus news from a host of biopharma quarterly earnings calls.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts